Lunella Biotech, Inc.
Records under this name other than the patents Lunella Biotech, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 29 patents it holds.
Showing 1 to 3 of 3 · Back to Lunella Biotech, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,229,657 | Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy Lapsed on the fee record Ended Jan 25, 2026 · USPTO record | Lapsed on the fee record | Ended Jan 25, 2026 | USPTO record |
| US 11,197,872 | Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs) Lapsed on the fee record Ended Dec 14, 2025 · USPTO record | Lapsed on the fee record | Ended Dec 14, 2025 | USPTO record |
| US 11,160,821 | Antimitoscins: Targeted Inhibitors of Mitochondrial Biogenesis for Eradicating Cancer Stem Cells Lapsed on the fee record Ended Nov 2, 2025 · High confidence | Lapsed on the fee record | Ended Nov 2, 2025 | High confidence |